Moneycontrol

Budget 2021

Associate Partners:

  • SMC
  • Samsung
  • Volvo

Moneycontrol

Budget 2021

Associate Partners:

  • SMCSamsungVolvo
you are here: HomeNewsGepowerindia
results
Jump to
22 Results Found
  • Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct Jan 18, 2021 07:52 PM IST

    Alembic Pha Q3 PAT seen up 19.9% YoY to Rs. 280.9 cr: ICICI Direct

    Net Sales are expected to increase by 17.7 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 1,422.8 crore, according to ICICI Direct.

  • India Inc’s profits to suffer hard knock from inventory losses – Part I Apr 29, 2020 09:49 AM IST

    India Inc’s profits to suffer hard knock from inventory losses – Part I

  • Alembic Pharma reports better numbers in Q3; here are highlights of analyst call Jan 25, 2020 04:28 PM IST

    Alembic Pharma reports better numbers in Q3; here are highlights of analyst call

    The company reported 33.8 percent jump in its Q3FY20 net profit to Rs 227.31 crore, EBITDA up 32.4 percent at Rs 325.46 crore

  • 'Q2 review: Bet on these 13 stocks for strong growth in FY21' Nov 19, 2019 01:13 PM IST

    'Q2 review: Bet on these 13 stocks for strong growth in FY21'

    Earnings downgrade continued in the September quarter but there were no fresh negatives in terms of outlook in management commentaries.

  • Alembic Pharma Q3 PAT seen up 7.7% YoY to Rs. 140.6 cr: ICICI Direct Jan 11, 2019 05:07 PM IST

    Alembic Pharma Q3 PAT seen up 7.7% YoY to Rs. 140.6 cr: ICICI Direct

    Net Sales are expected to increase by 21.4 percent Y-o-Y (down 9.5 percent Q-o-Q) to Rs. 1019.5 crore, according to ICICI Direct.

  • Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities Oct 17, 2018 06:17 PM IST

    Alembic Pharma Q2 PAT may dip 9.3% YoY to Rs. 110 cr: HDFC Securities

    Net Sales are expected to increase by 18.8 percent Y-o-Y (up 8.7 percent Q-o-Q) to Rs. 940 crore, according to HDFC Securities.

  • Alembic Pharma Q2 PAT may dip 4.5% YoY to Rs. 116.1 cr: ICICI Direct Oct 12, 2018 03:34 PM IST

    Alembic Pharma Q2 PAT may dip 4.5% YoY to Rs. 116.1 cr: ICICI Direct

    Net Sales are expected to increase by 20.7 percent Y-o-Y (up 10.4 percent Q-o-Q) to Rs. 952.3 crore, according to ICICI Direct.

  • Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey Apr 23, 2018 03:27 PM IST

    Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey

    Net Sales are expected to increase by 21.2 percent Y-o-Y (up 7 percent Q-o-Q) to Rs. 898.8 crore, according to KR Choksey.

  • Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities Apr 20, 2018 01:40 PM IST

    Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities

    Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.

  • Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey Jul 18, 2017 06:45 PM IST

    Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey

    Net Sales are expected to decrease by 6.86 percent Q-o-Q (down 6.29 percent Y-o-Y) to Rs 689.5 crore, according to KR Choksey. Alembic Pharma to report net profit at 86.3 crore down 16.70% year-on-year.

  • Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities Apr 17, 2017 01:04 PM IST

    Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities

    Net Sales are expected to increase by 2.6 percent Q-o-Q (up 26.3 percent Y-o-Y) to Rs 791.1 crore, according to ICICI Securities. Alembic Pharma to report net profit at 71.3 crore up 66.6% quarter-on-quarter.

  • Alembic Pharma Q3 profit seen down 60%, margin may shrink 20% Jan 25, 2017 09:02 AM IST

    Alembic Pharma Q3 profit seen down 60%, margin may shrink 20%

    Alembic Pharmaceuticals is expected to show massive degrowth in third quarter earnings due to unfavourable base in year-ago quarter. Profit is likely to fall 60 percent year-on-year to Rs 107 crore and revenue may slip 14 percent to Rs 794 crore in Q3, according to average of estimates of analysts polled by CNBC-TV18.

  • Alembic Pharma Q3 PAT may dip 16% to Rs 100 cr: HDFC Securities Jan 17, 2017 04:22 PM IST

    Alembic Pharma Q3 PAT may dip 16% to Rs 100 cr: HDFC Securities

    Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.

  • Alembic Pharma Q3 PAT may dip 22% to Rs 94 cr: ICICI Securities Jan 14, 2017 02:12 PM IST

    Alembic Pharma Q3 PAT may dip 22% to Rs 94 cr: ICICI Securities

    Net Sales are expected to decrease by 12.6 percent Q-o-Q (down 17.3 percent Y-o-Y) to Rs 762.3 crore, according to ICICI Securities.

  • Alembic Pharma Q3 PAT may dip 27.1% to Rs 87.3 cr: KR Choksey Jan 13, 2017 12:28 PM IST

    Alembic Pharma Q3 PAT may dip 27.1% to Rs 87.3 cr: KR Choksey

    Net Sales are expected to decrease by 18.4 percent Q-o-Q (down 22.1 percent Y-o-Y) to Rs 717.4 crore, according to KR Choksey.

  • We are planning 6-8 new launches this fiscal yr: Alembic Pharma Jul 29, 2016 02:35 PM IST

    We are planning 6-8 new launches this fiscal yr: Alembic Pharma

    Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

  • EBITDA margin came off unusually high base: Alembic Pharma Feb 04, 2015 03:14 PM IST

    EBITDA margin came off unusually high base: Alembic Pharma

    In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.

  • Alembic Pharma expects API biz to grow 10% in FY15 Oct 20, 2014 04:08 PM IST

    Alembic Pharma expects API biz to grow 10% in FY15

    The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.

  • See 20% EBITDA growth in FY14: Alembic Pharma Aug 07, 2013 03:50 PM IST

    See 20% EBITDA growth in FY14: Alembic Pharma

    In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

  • See 100-120 bps margin improvement in FY14: Alembic Pharma May 06, 2013 01:33 PM IST

    See 100-120 bps margin improvement in FY14: Alembic Pharma

    Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.

  • See pharma sector's margins to dip 314 bps in 3QFY13: Angel Jan 08, 2013 05:10 PM IST

    See pharma sector's margins to dip 314 bps in 3QFY13: Angel

    Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

  • ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma Feb 09, 2012 02:16 PM IST

    ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

    Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.

Sections